

Atara Biotherapeutics, Inc.  
Form 10-Q  
May 11, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

001-36548

(Commission file number)

ATARA BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware  
(State of incorporation)

46-0920988  
(I.R.S. Employer Identification No.)

701 Gateway Blvd., Suite 200

South San Francisco, CA 94080  
(Address of principal executive offices) (Zip code)

(650) 278-8930

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares of the registrant's Common Stock outstanding as of April 30, 2015 was 24,364,115 shares.

ATARA BIOTHERAPEUTICS, INC.

INDEX

|  | Page   |
|--|--------|
| PART I. FINANCIAL INFORMATION  |        |
| Item 1. <u>Financial statements (Unaudited)</u>  | 3      |
| <u>Condensed Consolidated and Combined Balance Sheets</u>  | 3      |
| <u>Condensed Consolidated and Combined Statements of Operations and Comprehensive Loss</u>           | 4      |
| <u>Condensed Consolidated and Combined Statements of Cash Flows</u>                                  | 5      |
| <u>Notes to Condensed Consolidated and Combined Financial Statements</u>                             | 6      |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | 14     |
| Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u>                            | 20     |
| Item 4. <u>Controls and Procedures</u>   | 20     |
| <br>PART II. OTHER INFORMATION   |        |
| <br>Item 1. <u>Legal Proceedings</u>   | <br>21 |
| <br>Item 1A. <u>Risk Factors</u>   | <br>22 |
| <br>Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>                       | <br>52 |
| <br>Item 3. <u>Defaults Upon Senior Securities</u>   | <br>52 |
| <br>Item 4. <u>Mine Safety Disclosures</u>   | <br>52 |
| <br>Item 5. <u>Other information</u>   | <br>52 |

|         |                          |    |
|---------|--------------------------|----|
| Item 6. | <u>Exhibits</u>          | 53 |
|         | <u>Signatures</u>        | 54 |
|         | <u>Index to Exhibits</u> | 55 |

Atara Biotherapeutics, Inc.

Condensed Consolidated and Combined Balance Sheets

(Unaudited)

(In thousands, except share and per share amounts)

|   | March<br>31,<br>2015 | December<br>31,<br>2014 |
|---|----------------------|-------------------------|
| <b>Assets</b>                                 |                      |                         |
| <b>Current assets:</b>                        |                      |                         |
| Cash and cash equivalents                     | \$71,329             | \$21,897                |
| Short-term available-for-sale investments     | 95,367               | 82,219                  |
| Prepaid expenses and other current assets     | 2,995                | 1,910                   |
| <b>Total current assets</b>                   | <b>169,691</b>       | <b>106,026</b>          |
| Property and equipment, net                   | 47                   | 48                      |
| Other assets                                  | 79                   | 48                      |
| <b>Total assets</b>                           | <b>\$169,817</b>     | <b>\$106,122</b>        |
| <b>Liabilities and stockholders' equity</b>   |                      |                         |
| <b>Current liabilities:</b>                   |                      |                         |
| Accounts payable                              | \$794                | \$440                   |
| Accrued compensation                          | 522                  | 1,225                   |
| Income tax payable                            | 1                    | 1                       |
| Other accrued liabilities                     | 2,197                | 1,058                   |
| <b>Total current liabilities</b>              | <b>3,514</b>         | <b>2,724</b>            |
| Other long-term liabilities                   | 209                  | 216                     |
| <b>Total liabilities</b>                      | <b>3,723</b>         | <b>2,940</b>            |
| <b>Commitments and contingencies (Note 5)</b> |                      |                         |